Therefore, the analysis of EGFR mutations in lung cancer is necessary for patients with EGFR mutations in non-small cell lung cancer (NSCLC) associating with poor prognosis and are likely to respond well to drugs targeting molecules on targeted tyrosine kinase domain inhibitors (erlotinib, gefitinib).